The content on this site is intended for healthcare professionals only
This series of animations investigates the use of PARP inhibitors for prostate cancer treatment and has been developed by Prof Phillip Cornford in association with ecancer.
The BRCA genes are an important part of the repair process for the daily onslaught of DNA damage, any faults can mean mistakes start to build up in the DNA, which increases the chances of the cell becoming cancerous.
This video explores the role of BRCA 1 and 2 genes in the HRR pathway and how it induces prostate cancer. Also, learn the mechanism of PARP inhibitors and how they can contribute to controlling prostate cancer, in this video.
To learn about when to test for prostate cancer click here.
To learn about who to test for prostate cancer click here.
To learn about how to test for prostate cancer click here.
To learn about metastatic prostate cancer and HRR defects click here.
To watch an expert panel discussion on the role of testing in prostate cancer treatment click here.
To watch a discussion on the latest on PARPi and other treatments for mCRPC click here here.
This programme has been supported by an unrestricted educational grant from AstraZeneca.
Best practice in precision medicine for prostate cancer
ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer
ESMO 2024: Optimising the personalisation of prostate cancer treatment
EAU 2024: Bladder cancer latest
Multiple myeloma in a resource constrained setting
First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer
Latest in PARP inhibitors and combination therapies for prostate cancer
Overview of the management of HER2-low breast cancer patients
Molecular profiling in prostate cancer: key challenges for clinical implementation
